Pricing consulting for single-specialty clinics: a working framework

Single-specialty clinics — cardiology, oncology, ophthalmology, fertility, orthopaedics — face a pricing problem that multi-specialty hospitals get to muddle through. When your revenue comes from twelve procedures instead of two hundred, every tariff line matters. A 5% mis-price on a single high-volume procedure moves the P&L visibly.

The working framework we use has three lenses. Cost-plus establishes the floor: direct consumables, staff time, allocated overhead, and target margin. Value-based establishes the ceiling: what's the outcome worth to the patient at this clinic versus the alternatives. Competitive is the reality check: what's the market actually clearing at in this catchment. A tariff set using only one lens under-optimises by 10–30% in either direction.

Cost-plus is where most clinics start and stop. The math is easy: add up your costs, mark up, done. The problem is that patients don't pay for your costs — they pay for outcomes, trust, and convenience. An IVF cycle at a reputation-top clinic commands 30–50% more than a tier-2 clinic's identical procedure, and it's priced that way because it's worth that much to the patient. Cost-plus pricing at the top clinic would give the upside away.

The TPA dimension adds another constraint. Cash-pay and TPA tariffs should differ by design, not by accident. Many clinics accidentally negotiate TPA rates close to their cash-pay rates because they use cash-pay as the anchor. The framework is inverted: TPA negotiated rates should use cost-plus as the ceiling (because TPAs won't pay value-based anyway), and cash-pay should use value-based. Differentiate on service level, not just price.

Package pricing is the other lever single-specialty clinics underuse. High-volume specialties — IVF, joint replacement, cataract — benefit from outcome-tiered packages instead of procedure-level pricing. Single-cycle versus multi-cycle IVF packages, premium-lens versus standard cataract, standard versus enhanced-recovery orthopaedic pathways. Packages reprice on outcome tiers without looking like price hikes.

A Mumbai fertility clinic we worked with rebuilt its tariff book around four outcome-tier packages. Cash-pay realisation lifted 22% over six months with no volume loss. TPA blended rate held flat — as expected — but the cash-pay uplift was enough to move EBITDA margin by roughly 300 basis points.